165739-83-3

Basic information

• Product Name: 4-chloro-loratadine
• Synonyms: 4-chloro-loratadine;4-(4,8-Dichloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester;Loratadine EP IMpurity C;1-Piperidinecarboxylic acid, 4- (4,8-dichloro-5,6-dihydro-11H- benzo[5,6]cyclohepta[1,2-b] pyridin-11-ylidene)-, ethyl ester;Loratadine EP Impurity C ( USP RC G );4,8-Dichloro-6,11-dihydro-11-[N-ethoxy carbonyl-4-piperidylidene]-5H-benzo[5,6] cyclohepta[1,2-b]pyridine
• CAS NO: 165739-83-3
• Molecular Formula: C22H22Cl2N2O2
• Molecular Weight: 417.32828
• Mol File: 165739-83-3.mol

Chemical Properties

• Boiling Point: 553.2±50.0 °C(Predicted)
• Appearance: /
• Density: 1.322±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: Acetone (Slightly), Chloroform (Slightly), Methanol (Slightly)
• PKA: 2.83±0.20(Predicted)
• CAS DataBase Reference: 4-chloro-loratadine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-loratadine(165739-83-3)
• EPA Substance Registry System: 4-chloro-loratadine(165739-83-3)

Safety Data

• Hazardous Substances Data: 165739-83-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-loratadine is used as an impurity in Loratadine (L469575) for the purpose of quality control and assurance in the manufacturing process. It helps in ensuring the purity and efficacy of the final product, as well as in the development of analytical methods for detecting and quantifying impurities in pharmaceutical formulations.

Relevant articles and documents

Selective Halogenation of Pyridines Using Designed Phosphine Reagents

Halopyridines are key building blocks for synthesizing pharmaceuticals, agrochemicals, and ligands for metal complexes, but strategies to selectively halogenate pyridine C-H precursors are lacking. We designed a set of heterocyclic phosphines that are installed at the 4-position of pyridines as phosphonium salts and then displaced with halide nucleophiles. A broad range of unactivated pyridines can be halogenated, and the method is viable for late-stage halogenation of complex pharmaceuticals. Computational studies indicate that C-halogen bond formation occurs via an SNAr pathway, and phosphine elimination is the rate-determining step. Steric interactions during C-P bond cleavage account for differences in reactivity between 2- and 3-substituted pyridines.